Topic:

Financials

Latest Headlines

Latest Headlines

Stormy Australia hearings on transfer pricing by drug firms invoke Sergeant Schultz

Multinational drug firms in Australia faced a string of barbs in hearings held by a Senate panel into transfer pricing that included a reference to a fictitious German World War II prison camp guard.

China's Universal prices IPO at $447M as HKEx shows attraction to healthcare

China's Universal Medical Financial & Technical Advisory Services priced its IPO at $447 million, FinanceAsia reported, showing further the ability of healthcare-focused companies, including biotechs, to raise cash on the Hong Kong Stock Exchange.

PE firm Madison Dearborn to buy Patterson rehab business for $715M

Patterson Companies is up almost 2% on news that it plans to sell its medical business to private equity firm Madison Dearborn Partners for $715 million in cash. The company has been looking to sell this unit, which is focused on physical rehabilitation products, in order to focus more closely on its higher growth businesses in dental and animal health.

ViewRay gets $50M in debt to back MRI-guided radiation therapy after IPO withdrawal

ViewRay has nabbed up to $50 million in debt financing from healthcare investor CRG after canceling a proposed $52 million IPO in April. The cash will go to help commercialize its MRI-guided radiation therapy as well as to refinance existing debt.

The massive med tech IPO: ConforMIS, Glaukos and Natera aim for $100M+

Custom knee implant maker ConforMIS has priced the latest major med tech IPO with its $135 million offering on July 1. Investor appetite for large med tech IPOs raising more than $100 million remains whetted, despite the encroachment of the summer doldrums that can slow Wall Street activity to a crawl.

India's Marksans Pharma buys U.S.-based Time-Cap, a trend in the making?

More than a few analysts and company executives are watching Indian drug companies in expectations of consolidation among smaller players and possibly daring moves by mid-cap and larger at home and abroad.

Investors punish micro-cap EnteroMedics as it raises $35M to market recently approved obesity device

Wall Street remains skeptical of the first obesity device to be approved by the FDA in more than a decade. The agency approved VBLOC Vagal Blocking Therapy via the EnteroMedics Maestro System in January based on less-than-stellar pivotal data and a mixed panel review. Some investors are backing the company in its follow-on, which has raised $35 million, but at very steep terms.

No artful tax dodging here, drug firms tell Australia transfer-price inquiry

We checked and everything is done correctly on our tax obligations, 9 drug companies said in separate submissions ahead of testimony on July 1 to an Australian Senate inquiry on tax avoidance.

Aratana shares soar on positive trial of appetite stimulator for dogs

Late in the day on Friday, Kansas City animal health company Aratana Therapeutics announced successful results of a pivotal trial of capromorelin (AT-002), which stimulates appetite in dogs. The company's shares skyrocketed 25% to $16.74 in after-hours trading.

Blurred lines in Japan's vision for healthcare in next two decades

Japan's efforts to blend cost savings and innovation are so tied up in broader national goals to revive the deflation-hit economy that a plan had to be drawn up for the next two decades--but the documents and slides to describe the ideas seem to deftly avoid any look at the hard choices needed.